Keyphrases
Acquired Vulnerability
100%
Adaptive Behavior
16%
Anti-MEK
16%
Antitumor Effect
16%
Blockage
16%
Cancer Medicines
16%
Combination Strategy
16%
Drug Resistance
66%
Endoplasmic Reticulum
16%
Endoplasmic Reticulum Stress (ER stress)
33%
Eukaryotic Translation Initiation Factor 4E (eIF4E)
100%
First-line Chemotherapy
16%
Heat Shock Protein 90 (Hsp90)
100%
In Cancer
16%
KRAS mutant Lung Cancer
100%
KRAS-mutant Cancer
16%
Lung Cancer Cells
50%
Malignant Tumor
16%
Multidrug-resistant
100%
Novel Therapeutics
16%
Pemetrexed
16%
Protein Turnover
16%
Rational Combinations
16%
Receptor Tyrosine Kinase
16%
Resistant Cancer Cells
16%
Stress Relief
16%
Stress Signaling
16%
Survival Pathways
16%
Targeted Therapy
16%
Therapeutic Avenues
16%
Trametinib
33%
Tumor Heterogeneity
50%
Unfolded Protein Response
100%
Vulnerability
16%
Medicine and Dentistry
Cancer Cell
66%
Drug Resistance
66%
Endoplasmic reticulum
16%
Endoplasmic Reticulum Stress
33%
First-Line Chemotherapy
16%
Initiation Factor 4E
100%
Lung Cancer
100%
Malignant Neoplasm
50%
Medicine
16%
Pemetrexed
16%
Protein Tyrosine Kinase
16%
Targeted Therapy
16%
Trametinib
33%
Tumour Heterogeneity
33%
Unfolded Protein Response
100%
Biochemistry, Genetics and Molecular Biology
Cancer Cell
50%
Drug Resistance
50%
Endoplasmic Reticulum Stress
25%
Eukaryotic Translation
100%
Initiation Factor
100%
KRAS
100%
Pemetrexed
12%
Protein Degradation
12%
Receptor Tyrosine Kinase
12%
Trametinib
25%
Unfolded Protein Response
100%
Pharmacology, Toxicology and Pharmaceutical Science
Drug Resistance
66%
First-Line Chemotherapy
16%
Initiation Factor 4E
100%
Lung Cancer
100%
Malignant Neoplasm
66%
Neoplasm
33%
Pemetrexed
16%
Protein Tyrosine Kinase
16%
Trametinib
33%